Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Pulmonary/Respiratory Diseases | Family Medicine
 Disease Category: Non-Small Cell Lung Cancer
Location: United States, CA

Trial Information

A Pilot Trial to Evaluate Cyclooxygenase 2 Inhibitor-Mediated Modulation of T Regulatory Cells in Advanced Non-Small Cell Lung Cancer (NSCLC)

You have been asked to participate in this research study because you have non-small cell lung cancer (NSCLC) that is advanced (has spread to other parts of your body). The purpose of this study is to find out the best dose of Celebrex for reducing the amount of a specific type of white blood cell and other cells that help them develop and function. Researchers would also like to find out how Celebrex affects how the cells work. Lastly, researchers would like to find out what happens to the immune system when Celebrex is given for one week. You will receive Celebrex on this study on this study is expected to last 7 days. Your participation in this study is expected to last 8 to 21 days, depending on how many days lapse between screening tests and the 7 days of receiving Celebrex.

Patient Inclusion/Exclusion Criteria:


- See http://clinicaltrials.coh.org for additional information.


City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Map

Research Center Information: City of Hope

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.